Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
DiaSorin S.p.A. (DIA.MI)
EUR69.46
-0.22 (-0.32%)
IT MIL Healthcare Medical - Diagnostics & Research
Address
Via Crescentino snc 13040
Saluggia, VC, IT
Saluggia, VC, IT
CEO
Carlo Rosa
Website
int.diasorin.com
IPO
2007-07-19
ISIN IT0003492391
Also trades on
Italian Stock Exchange · DIA.MI (EUR)
Other OTC · DSRLF (USD)
Description
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR69.46
-0.22 (-0.32%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
311.5K
Beta
0.68
Float Shares
20.73M
Free Float %
39.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.18% | +6.48% | +11.66% | -7.49% | +13.66% | +0.00% | -29.21% | -34.89% | -50.54% | +29.42% | +445.02% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
69.46
DCF (Unlevered)
94.83
+36.5%
DCF (Levered)
124.20
+78.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
42% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 3 | -1 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 2 | 0 |
Quality scores
Altman Z-Score
3.38
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+0.8% Q1'26: -8.3% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-18.1% Q1'26: -25.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+22.9% Q1'26: +20.2% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+25.5% ★ Q1'26: +20.6% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+10.0% ★ Q1'26: +8.0% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.1% Q1'26: -1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×1.83× Q1'26: 2.61× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 11 EPS Ana. |
Dec 2027 13 Rev. Ana. 11 EPS Ana. |
Dec 2028 12 Rev. Ana. 8 EPS Ana. |
Dec 2029 11 Rev. Ana. 6 EPS Ana. |
Dec 2030 6 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
499.18M
est: 497.28M (+0.4%)
|
569.31M
est: 569.12M (+0.0%)
|
637.49M
est: 638.09M (-0.1%)
|
669.20M
est: 672.29M (-0.5%)
|
706.32M
est: 713.06M (-0.9%)
|
881.31M
est: 875.71M (+0.6%)
|
1.24B
est: 1.22B (+1.5%)
|
1.36B
est: 1.36B (-0.1%)
|
1.15B
est: 1.16B (-1.1%)
|
1.19B
est: 1.19B (-0.5%)
|
1.20B
est: 1.20B (-0.6%)
|
1.23B
1.21B – 1.24B
+2.2% YoY
|
1.31B
1.28B – 1.33B
+6.5% YoY
|
1.39B
1.39B – 1.39B
+6.2% YoY
|
1.48B
1.45B – 1.50B
+6.4% YoY
|
1.57B
1.54B – 1.59B
+6.4% YoY
|
| EBITDA |
185.80M
est: 181.26M (+2.5%)
|
216.56M
est: 207.44M (+4.4%)
|
242.69M
est: 232.58M (+4.3%)
|
254.20M
est: 245.05M (+3.7%)
|
273.14M
est: 259.91M (+5.1%)
|
383.62M
est: 319.19M (+20.2%)
|
504.56M
est: 444.65M (+13.5%)
|
479.71M
est: 496.63M (-3.4%)
|
333.40M
est: 406.22M (-17.9%)
|
399.04M
est: 416.86M (-4.3%)
|
432.81M
est: 420.42M (+2.9%)
|
429.78M
424.37M – 434.74M
+2.2% YoY
|
457.55M
446.76M – 464.01M
+6.5% YoY
|
485.73M
485.34M – 486.11M
+6.2% YoY
|
516.65M
507.21M – 523.29M
+6.4% YoY
|
549.53M
539.49M – 556.60M
+6.4% YoY
|
| EBIT |
151.85M
est: 139.37M (+9.0%)
|
171.26M
est: 159.50M (+7.4%)
|
183.00M
est: 178.83M (+2.3%)
|
207.20M
est: 188.42M (+10.0%)
|
220.37M
est: 199.85M (+10.3%)
|
324.80M
est: 245.43M (+32.3%)
|
421.15M
est: 341.89M (+23.2%)
|
360.37M
est: 381.86M (-5.6%)
|
230.58M
est: 299.00M (-22.9%)
|
270.00M
est: 306.83M (-12.0%)
|
304.57M
est: 309.45M (-1.6%)
|
316.34M
312.35M – 319.99M
+2.2% YoY
|
336.78M
328.84M – 341.53M
+6.5% YoY
|
357.52M
357.24M – 357.80M
+6.2% YoY
|
380.28M
373.33M – 385.17M
+6.4% YoY
|
404.48M
397.09M – 409.68M
+6.4% YoY
|
| Net Income |
100.42M
est: 99.82M (+0.6%)
|
112.38M
est: 115.23M (-2.5%)
|
139.88M
est: 137.09M (+2.0%)
|
158.13M
est: 155.60M (+1.6%)
|
175.74M
est: 172.82M (+1.7%)
|
247.87M
est: 244.88M (+1.2%)
|
310.97M
est: 317.07M (-1.9%)
|
240.91M
est: 295.79M (-18.6%)
|
159.85M
est: 167.74M (-4.7%)
|
188.11M
est: 212.74M (-11.6%)
|
155.62M
est: 214.38M (-27.4%)
|
215.61M
183.08M – 248.13M
+0.6% YoY
|
205.30M
200.17M – 277.62M
-4.8% YoY
|
275.37M
246.35M – 304.38M
+34.1% YoY
|
271.46M
265.02M – 276.00M
-1.4% YoY
|
283.81M
277.07M – 288.55M
+4.5% YoY
|
| SGA |
153.54M
est: 145.15M (+5.8%)
|
169.51M
est: 166.12M (+2.0%)
|
187.87M
est: 186.25M (+0.9%)
|
200.27M
est: 196.24M (+2.1%)
|
212.34M
est: 208.14M (+2.0%)
|
208.16M
est: 255.61M (-18.6%)
|
304.61M
est: 356.08M (-14.5%)
|
406.74M
est: 397.70M (+2.3%)
|
414.41M
est: 354.82M (+16.8%)
|
376.14M
est: 364.11M (+3.3%)
|
364.18M
est: 367.22M (-0.8%)
|
375.39M
370.66M – 379.72M
+2.2% YoY
|
399.65M
390.23M – 405.29M
+6.5% YoY
|
424.26M
423.93M – 424.59M
+6.2% YoY
|
451.27M
443.03M – 457.07M
+6.4% YoY
|
479.99M
471.22M – 486.16M
+6.4% YoY
|
| EPS |
1.83
est: 1.79 (+2.4%)
|
2.05
est: 2.06 (-0.6%)
|
2.54
est: 2.45 (+3.5%)
|
2.85
est: 2.79 (+2.3%)
|
3.21
est: 3.09 (+3.8%)
|
4.53
est: 4.38 (+3.4%)
|
5.44
est: 5.68 (-4.1%)
|
4.17
est: 5.29 (-21.2%)
|
2.87
est: 3.01 (-4.8%)
|
3.37
est: 3.82 (-11.7%)
|
2.76
est: 3.85 (-28.2%)
|
3.90
3.27 – 4.43
+1.5% YoY
|
4.33
3.58 – 4.96
+11.0% YoY
|
4.88
4.40 – 5.44
+12.7% YoY
|
4.85
4.74 – 4.93
-0.7% YoY
|
5.07
4.95 – 5.16
+4.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
421.38M
OE per share TTM
7.56
Owner's Yield
11.57%
Maintenance CapEx ratio
46.24%
Maint CapEx / Avg PPE
20.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 97 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA | 0.35% | 2.51M | 0.40% |
| 2 | WisdomTree Europe Hedged Equity Fund HEDJ | 0.26% | 4.79M | 0.58% |
| 3 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.26% | 1.92M | 0.33% |
| 4 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.25% | 2.63M | 0.58% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.24% | 816.5K | 0.23% |
| 6 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.24% | 816.5K | 0.23% |
| 7 | WisdomTree Europe Equity UCITS ETF - USD Hedged HEDJ.L | 0.24% | 267.1K | 0.58% |
| 8 | WisdomTree Europe Equity UCITS ETF - USD Hedged Acc HEDK.L | 0.24% | 267.1K | 0.58% |
| 9 | WisdomTree Europe Equity UCITS ETF - GBP Hedged HEDP.L | 0.24% | 357.2K | 0.35% |
| 10 | WisdomTree Europe Equity UCITS ETF - EUR Acc WTDF.DE | 0.24% | 304.3K | 0.32% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
94.8K
Shares Outstanding
53.00M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carlo Rosa | Chief Executive Officer, GM & Executive Director | 2M | male |
| Chen Menachem Even | Chief Commercial Officer, Senior Corporate Vice President of Commercial Operations & Executive Director | 937.7K | — |
| Amelia Parente | Senior Corporate Vice President of Human Resources | — | female |
| Fabrizio Bonelli | Chief Scientific Officer | — | male |
| Luigi Cicchese | Senior Corporate Vice President of Systems & Engineering | — | male |
| Piergiorgio Pedron | Senior Corporate Vice President, Chief Financial Officer & Corporate Accounting Documents Officer | — | male |
| Riccardo Fava | Corporate Vice President of Communication, ESG & Investor Relations | — | male |
| Rita Maffei | Senior Corporate Vice President of Quality, Regulatory & Clinical Affairs | — | female |
| Alberto Campani | Chief Executive Officer, GM of Diasorin Italy & Vice President of Global Immuno Operations | — | male |
| Ulisse Spada | Corporate Vice President, Head of the Legal Department, Secretary & General Counsel | — | male |
| Alberto Donati | Chief Financial Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DIA.MI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
